Trial Profile
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Sep 2023
Price :
$35
*
At a glance
- Drugs Tisotumab-vedotin (Primary) ; Brimonidine
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms innovaTV 208
- Sponsors Seagen
- 01 Jan 2023 This trial has been discontinued in Italy, according to European Clinical Trials Database
- 09 Jun 2022 This trial has been Discontinued in Spain, according to European Clinical Trials Database.
- 07 Apr 2022 This trial has been Discontinued in Ireland, according to European Clinical Trials Database.